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ABSTRACT
Graft-versus-host disease (GVHD) is themost significant clinical problem that arises after allogeneic hematopoietic
cell transplantation. Because chemokines induced by proinflammatory conditioning treatment may promote T-cell
migration into GVHD target tissues, we addressed the influence of conditioning on chemokine expression in
GVHD target organs. Our results showed that (1) conditioning leads to rapid and transient chemokine upregulation
in GVHD target tissues before the time of GVHD-associated T-cell infiltration; (2) conditioning intensity and
mouse strain influence chemokine expression in GVHD target organs; and (3) compared with syngeneic bone
marrow transplantation, allogeneic bone marrow transplantation led to marked amplification of chemokine expres-
sion in GVHD target organs after myeloablative conditioning. This is also reflected by chemokine protein
expression that is measured in the serum and colon. Intestines showed the greatest sensitivity to conditioning
intensity, and chemokines affecting T-helper type 1 cells (eg, interferon -inducible protein 10 [CXCL10]) were
most strongly expressed there after conditioning and during GVHD. However, severity of GVHD was not
significantly different between recipients of CXCR3/ or CXCR3/ splenocytes, indicating that this chemokine
pathway does not play a critical role. In summary, our data show that conditioning and recipient strain influence
chemokine expression in GVHD target organs and that GVH alloreactivity markedly amplifies this expression, thus
contributing to the inflammatory cascade associated with tissue GVHD.
© 2006 American Society for Blood and Marrow Transplantation
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GNTRODUCTION
Allogeneic bone marrow transplantation (BMT) is
he only known curative treatment option for a num-
er of malignant diseases, and tumor responses de-
end to a signiﬁcant extent on an immunologically
ediated graft-versus-leukemia (GVL) response [1,2].
owever, in the clinical setting, GVL effects have f
B&MTrequently been linked to the development of GVHD
3]. This GVL reaction is primarily alloantigen driven
ut can occur in the absence of GVHD, as demon-
trated in preclinical models [4,5] and in patients [3].
owever, GVL effects are counterbalanced by
VHD, often leading to failure of improved relapse-ree survival to translate into improved overall sur-
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6ival. Therefore, strategies are needed to inhibit
VHD without mitigating GVL effects.
The pathogenesis of GVHD is complex and inﬂu-
nced in part by the major or minor histocompatibility
ntigenic disparities between donor and recipient and
he presence of host-derived antigen-presenting cells [6].
ther factors contributing to the development of
VHD include sequelae of conditioning therapy-in-
uced toxicity. A large body of data has shown clearly
hat conditioning-induced tissue damage and cytokine
ecretion play a pivotal role in the development of
VHD [7-13]. This proinﬂammatory milieu is thought
o critically inﬂuence the development of GVHD. Thus,
dministration of large numbers of fully major histocom-
atibility complex (MHC)-mismatched T cells on day 0
eads to the development of uniformly lethal GVHD in
ice. However, administration of donor T cells after a
elay of 5-8 weeks after BMT, when the inﬂammatory
ilieu created by the conditioning therapy has presum-
bly subsided, does not induce GVHD [5,7]. When
hese nontolerant donor T cells are given to established
ixed hematopoietic chimeras, conversion to full-donor
himerism ensues, demonstrating that donor T cells can
ediate a GVH response (GVHR) that is conﬁned to
he lymphohematopoietic system (LGVHR) [7]. When
onor lymphocyte infusions (DLIs) are given to estab-
ished mixed chimeras, the LGVHR leads to powerful
VL effects without GVHD [5,14]. We have hypothe-
ized that the absence of GVHD in this setting is related
o the disappearance of the proinﬂammatory milieu in
he GVHD target tissues over time after conditioning
herapy [5,14].
Chemokines are predominantly small molecules
8-14 kd) that bind to a family of heterotrimeric G-
rotein–coupled receptors with a 7-transmembrane–
panning serpentine structure and play an important
ole in leukocyte trafﬁcking [15]. Chemokines are
nvolved in a variety of inﬂammatory and infectious
onditions, including GVHD [16-21]. We hypothe-
ized that conditioning-induced upregulation of che-
okines and adhesion molecules in the epithelial
VHD target tissues plays a major role in converting
GVHR into GVHD. We sought to delineate the
ffect of myeloablative versus nonmyeloablative con-
itioning and other recipient factors on the expression
f chemokines in response to conditioning and allo-
eneic BMT. Because T-helper types 1 and 2 (Th1
nd Th2, respectively) have different roles in inducing
VHD in different target tissues and this speciﬁcity is
omewhat strain dependent [22], we evaluated Th1-
nd Th2-attracting chemokines in 2 different strain
ombinations. Our data demonstrate that organ-spe-
iﬁc chemokine expression patterns occur after con-
itioning, and this expression depends on condition-
ng intensity and genetic background. ﬁ
24ETHODS
nimals
Female C57BL/6 (B6: H2b) and BALB/c (H2d)
ecipient mice were purchased from Frederick Cancer
esearch Facility (National Cancer Institute, Freder-
ck, MD) and used after 8 weeks of age. CXCR3/
ice were generated as described previously [23] and
ackcrossed 10 times to the B6 strain. All mice were
oused in autoclaved micro-isolator environments,
nd all manipulations were performed in a laminar
ow hood.
onmyeloablative Conditioning
Nonmyeloablative conditioning was performed as
reviously described [24]. Brieﬂy, mice received de-
leting doses of anti-CD8 monoclonal antibody
mAb) 2.43 and anti-CD4 mAb GK1.5 intraperitone-
lly on day 5 and 200 mg/kg cyclophosphamide
Cytoxan, CTX, Pharmacia, Peapack, NJ) intraperito-
eally on day 1. Puriﬁed mAbs were prepared at the
ational Cell Culture Center (Minneapolis, Minn).
n day 0, the mice received 7 Gy thymic irradiation
rom a cobalt 60 source. Because our previous studies
ave shown that these high doses of CD4- and CD8-
epleting antibodies deplete donor T cells that are
iven on the day of BMT, we could not compare the
ffects of allogeneic GVH-inducing inocula (versus
yngeneic BMT) in recipients of this regimen, and we
onﬁned studies in the nonmyeloablative model to an
nalysis of the effect of conditioning alone on chemo-
ine expression.
ethal Conditioning and Induction of GVHD
Syngeneic or allogeneic control mice received le-
hal doses (8-9.75 Gy, depending on strain; dose rate,
8 Gy/min cesium 137 source; JL Shepherd Mark I
rradiator, San Fernando, CA) of total body irradia-
ion (TBI) and were reconstituted within 4-8 hours
ith an intravenous inoculum (5  106 cells) of syn-
eneic (syngeneic control) or allogeneic (allogeneic
ontrols) bone marrow cells (BMCs). For induction of
VHD, animals received donor splenocytes in addi-
ion to allogeneic BMCs. In BALB/c recipients,
VHD was induced by using 8-Gy TBI on day 0
ollowed by administration of 1  107 B6 BMCs and
3  106 B6 spleen cells. GVHD was induced in B6
ecipients by using 9.75-Gy TBI followed by recon-
titution with 1  107 BALB/c BMCs and 13  106
ALB/c spleen cells.
ssessment of GVHD
Animals from different groups were randomized
n cages. Body weights were measured on the day of
ransplantation and then twice each week during the
rst month and once a week after that. Animals were
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Chemokine Expression and GVHD
Blso scored for clinical evidence of GVHD by assess-
ent of changes in skin (ie, alopecia, inﬂamed or scaly
kin), generalized signs (fur texture, posture, and in-
ammation of the eyes), and diarrhea. Each parameter
as quantiﬁed by scoring as previously described [25].
istopathology
For histopathologic analysis and chemokine ex-
ression proﬁles, animals were killed on the indicated
ays. Samples from small and large intestines, liver,
kin (from the head), and lungs were ﬁxed in 10%
ormalin, processed, and analyzed by a blinded pathol-
gist as described previously [25].
Nase Protection Assay
RNA was extracted from GVHD target tissues by
nap freezing and homogenizing tissues in TRIzol (In-
itrogen, Carlsbad, CA) using a Polytron tissue homog-
nizer. Chemokine expression was analyzed with Ribo-
uant kits and the CK-5 and mCK5b template sets
Pharmingen, San Diego, CA) according to the manu-
acturer’s protocol. Ten micrograms of total RNA was
sed per sample. Radioactive labeling was performed
ith [32]-cytidine triphosphate (CTP) (NENDupont,
oston, MA). After digestion of single-strand RNA, the
NA pellet was resolved on 6% polyacrylamide gels
sing the SequiGen chamber (BioRad, Hercules, CA).
NA levels were quantiﬁed using a phosphorimaging
ystem (Storm, GE Healthcare, Buckinghamshire, UK).
xpression intensity for each band was normalized to the
ousekeeping gene (L32) within each sample.
orthern Blot Analysis
Expression of CXCR3 ligands was assessed by
orthern blotting instead of RNase protection assay
ecause analysis of interferon -inducible protein 10
CXCL10) is not feasible with the Pharmingen CK5
emplate set due to the presence of a sequence poly-
orphism within the CXCL10 cDNA that produces
rotected fragments that migrate the same distance as
he CCL2 probe [26]. Total RNA was prepared by
sing TRIzol as described above, and 10 g was sub-
ected to gel electrophoresis on a 1.1% formaldehyde/
.2% agarose gel and transferred to a nylon mem-
rane (Appligene, Heidelberg, Germany). After UV
rosslinking, the membrane was prehybridized
ExpressHyb solution, Clontech, Heidelberg, Ger-
any) at 68°C for 30 minutes. Blots were hybridized
ith 32PdCTP random primer labeled (Ambion,
ustin, Tex), full-length cDNA probes (CXCL10,
ig [CXCL9], I-TAC [CXCL11]) and glyceralde-
yde-3-phosphate dehydrogenase (GAPDH) over-
ight at 68°C. Thereafter, membranes were washed
or 40 minutes at room temperature in 2 standard
aline citrate/.1% sodium dodecylsulfate and then for a
B&MT0 minutes at 50°C in .5% standard saline citrate/.1%
odium dodecylsulfate.
ultiplex Analysis
The LabMap technology (Luminex Corp, Austin,
X) combines the principle of a sandwich immuno-
ssay with ﬂuorescent bead-based technology, thereby
llowing individual and multiplex analyses of up to
00 different analytes in a single microtiter well
27,28]. The LabMap serum and tissue lysate assays
ere performed in 96-well microplate format accord-
ng to the protocol by BioSource International (Cam-
rillo, CA). A ﬁlter-bottom, 96-well microplate (Mil-
ipore, Billerica, Mass) was blocked for 10 minutes
ith phosphate buffered saline/bovine serum albumin.
o generate a standard curve, 5-fold dilutions of ap-
ropriate standards were prepared in serum diluent.
tandards and experimental sera/tissue lysate were pi-
etted at 50 L/well in duplicate and mixed with 50
L of the bead mixture. The microplate was incu-
ated for 1 hour at room temperature on a microtiter
haker. Wells were then washed 3 times with washing
uffer using a vacuum manifold. Phycoerythrin-con-
ugated secondary antibody was added to the appro-
riate wells and wells were incubated for 45 minutes in
he dark with constant shaking. Wells were washed
wice, assay buffer was added to each well, and samples
ere analyzed with the Bio-Plex suspension array sys-
em (Bio-Rad Laboratories, Hercules, CA). Analysis
f experimental data was performed by using 5-para-
etric curve ﬁtting.
reparation of Tissue Lysates
Tissues were freshly isolated and snap frozen in liq-
id nitrogen and stored at 80°C until use. Tissue
amples were lysed with lysis buffer (10 mM HEPES,
H 7.9; 10 mM KCl; .1 mM ethylenediaminetetraacetic
cid; .1 mM ethylene-glycol-tetra-acetic acid (EGTA); 1
M dithiothrietol; .5 mM phenyl methyl sulfonyl ﬂuo-
ide, .1% Nonidet NP-40). Tissue homogenates were
sed for multiplex analysis.
ESULTS
xpression of Chemokines in Liver and Skin after
ethal TBI
GVHD was induced in fully MHC-mismatched
llogeneic BMT recipients in the B6¡BALB/c and
he reverse strain combination. To assess the inﬂuence
f conditioning alone on chemokine expression, con-
rol animals received syngeneic BMT. GVHD target
rgans were harvested from 3 mice per group on days
3, 5, 7, and 10 and analyzed for histopatho-
ogic signs of GVHD and chemokine mRNA expres-
ion using RNase protection assays or northern blot
nalysis.
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6In the GVHD group, histologic analysis revealed
ymphocyte inﬁltration on day5 after allogeneic BMT
n liver and gut, but not sooner, with the exception of 1
nimal that showed signs of colon inﬁltration on day3.
n contrast, recipients of syngeneic BMCs showed only
ild signs of radiation-induced damage and subsequent
igure 1. A, Chemokine mRNA expression in the liver after syngeneic
nd allogeneic BMT. As described in the Methods section, BALB/c
ice were lethally irradiated and reconstituted with syngeneic bone
arrow alone or allogeneic B6 bone marrow plus spleen cells. Animals
ere killed on days 3, 5, 7, and 10. RNA was extracted and subjected
o the RNAse protection assay. Each lane corresponds to 1 animal.
en micrograms of RNA was assayed for each animal. B, Analysis of
hemokine expression in the liver by RNase protection assay. Expres-
ion intensity for each band was normalized within each sample to the
ousekeeping gene (L32) and is presented as relative expression com-
ared with untreated mice. Means 	 SD of 2-3 animals per group are
epicted at each time point. Asterisks denote signiﬁcant differences (P
.05) between syngeneic and allogeneic BMT recipients at the indi-
ated time points. Results are shown from 1 of 2 similar experiments
ith 2-3 animals per group at each time point.
26egeneration (data not shown). Only very mild histologic
hanges were observed in the skin at days 3-10.
As depicted in Figure 1A, BALB/c syngeneic
MT controls showed a slight and transient increase
n monocyte chemoattractant protein 1 (CCL2) and T
ell activation-3 (TCA-3) (CCL1) RNA expression in
he liver compared with untreated controls, from
hich chemokine/L32 mRNA ratios are used as the
enominator in the collated data shown in Figure 1B.
t the earliest time point (ie, day 3), chemokine
xpression in the liver was not statistically signiﬁcantly
ifferent between syngeneic recipients and GVHD
nimals (Figure 1B). At later time points, however,
ecipients of allogeneic, fully MHC-mismatched B6
pleen cells and BMCs exhibited a statistically (P 
05) signiﬁcant increase in chemokine expression in
he liver compared with syngeneic recipients. In ad-
ition to CCL2 and CCL1, other chemokines, includ-
ng RANTES (CCL5) and monocyte chemoattractant
rotein 1 (CCL3), were expressed in the liver of
VHD animals but not in syngeneic recipients by
ays 5, 7, and 10.
We also studied chemokine expression in the
everse strain combination (BALB/c¡B6). In this
ombination, livers showed upregulation of multi-
le chemokines after allogeneic transplantation,
eaking between days 5 to 7, although not al-
ays reaching statistical signiﬁcance (data not
hown). Strain differences were observed regarding
iver chemokine expression after syngeneic BMT,
ith B6 recipients showing higher levels of CCL5,
CL4, CCL3, and CCL2 compared with BALB/c
ecipients on day 7 after BMT (data not shown).
Except for CCL2, which was signiﬁcantly upregu-
ated on days 5 (4.6-fold) and 7 (3.6-fold) after
llogeneic BMT, there was no signiﬁcant (2-fold)
ncrease in expression of most chemokines studied in
he skin after allogeneic or syngeneic BMT in the
ALB/c¡B6 strain combination. Even less marked
hanges were observed in the B6¡BALB/c strain
ombination (data not shown).
xpression of Chemokines in the Colon
In B6 recipients, we detected a slight increase in
he expression of CCL3 (Figure 2) in the large bowel
n day 3 after syngeneic BMT. With the exception
f CXCL1 (monocyte chemoattractant protein 2) and
CL2, and in contrast to the liver, statistically signif-
cant (P  .05) upregulation of all chemokines studied
as evident at all time points (even day 3) in the
olon of allogeneic recipients. Because colon inﬁltra-
ion with lymphocytes was not apparent at this early
ime point, these results suggest that the systemic
VH allogeneic response induced massive upregula-
ion of local chemokine expression in the colon.
Similar patterns of chemokine expression were
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Chemokine Expression and GVHD
Bbserved in the B6¡BALB/c strain combination, but
ALB/c recipients showed higher levels of chemokine
xpression after GVHD induction, as presented in
able 1 for the colon. Some differences in chemokine
xpression were also observed among lethally irradi-
ted B6 versus BALB/c recipients of syngeneic BMT.
igure 2. Analysis of chemokine expression in the colon by RNase
rotection assay. Expression intensity for each band was normalized
ithin each sample to the housekeeping gene (L32) and is presented
elative to expression in normal recipients. Means 	 SD of 2-3
nimals per group per time point are depicted. Asterisks denote
igniﬁcant differences (P  0.05) between syngeneic and allogeneic
MT recipients at the indicated time points. Results from 1 of 2
imilar experiments are shown.or example, signiﬁcantly increased levels of CCL3 m
B&MTnd CCL4 mRNA were detected in colons of BALB/c
ice on day 7 (and day 3 for CCL4) compared with
6 recipients.
Previous studies have suggested that T-cell polar-
zation affects organ tropism of GVHD and that Th1
ells are critical for intestinal GVHD [22]. To eluci-
ate the effect of conditioning and GVHD induction
n expression of Th1-attracting chemokines in the
astrointestinal system, we analyzed the expression of
h1-attracting chemokine ligands of the Th1-associ-
ted CXCR3 receptor in the B6¡BALB/c strain com-
ination. As shown in Figure 3, undetectable or low
evels of the CXCR3 ligand mRNAs were constitu-
ively expressed in the large bowel. However, after
ethal irradiation with syngeneic BMT, we detected a
igniﬁcant, but short-lived, upregulation of CXCL10,
hich peaked on day 3 and almost completely dis-
ppeared by day 5. Conditioning had no major ef-
ect on the expression of CXCL11 and CXCL9. Al-
ogeneic transplantation and induction of GVHD led
o marked and sustained upregulation of expression of
ll CXCR3 ligands examined, with CXCL10 and
XCL9 peaking at days 5-7. Weak CXCL11 expres-
ion, peaking on day 5, was observed.
ffect of GVHR on Systemic and Local Protein
xpression of Chemokines
Because of the observation that conditioning and
VHR led to a marked upregulation of chemokine
RNA expression in GVHD target organs, we as-
essed systemic levels of chemokines in the serum by
sing multiplex analysis. As shown in Figure 4A, se-
um levels of CXCL10, CCL3, CCL2, and CCL5
ere determined after induction of GVHD in the
ully MHC-mismatched BALB/c¡B6 strain combi-
ation. To assess the inﬂuence of conditioning (with-
ut GVHD) on chemokine expression, control ani-
als received syngeneic or allogeneic BMT alone.
igniﬁcant increases in systemic chemokine levels
bove those in normal untreated B6 mice were ob-
erved only after induction of GVHD. On day 3
fter BMT, serum levels of CCL2 and CXCL10 were
igniﬁcantly higher in animals with GVHD than in syn-
eneic controls. Further, animals with GVHD showed a
tatistically signiﬁcant increase in serum levels of CCL3,
CL5, and CXCL10 on day6 in comparison with day
3. In comparison with syngeneic controls, CCL5 and
XCL10 levels were signiﬁcantly higher on day 6 in
nimals with GVHD (CCL2 levels were of borderline
igniﬁcance, P 
 .07).
In addition to serum we studied the effect of con-
itioning with or without induction of GVHD on the
rotein expression of the above-mentioned chemo-
ines in colon lysates using the Luminex Multiplex
ssay (Figure 4B). Colon tissue from untreated normal
6 and BALB/c controls did not express these che-
okines (data not shown). In line with RNA expres-
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6ion data and in contrast to serum protein data, we
etected a signiﬁcant upregulation of chemokines, in
articular CXCL10, in conditioned animals without
VHD (receiving syngeneic or allogeneic BMT ver-
igure 3. Expression of CXCR3 ligand mRNA in the colon after m
ice were lethally irradiated and reconstituted with syngeneic bone
nimals were killed on days 3, 5, 7, and 10. RNA was extracted and s
able 1. Effect of Mouse Strain on Chemokine Expression in the Colon
Mean Fold Increase in Expression
PBALB/c¡B6 B6¡BALB/c
CL5
D3 0.46 2.30 <
D5 0.86 8.75
D7 8.19 19.70 <
D10 7.09 12.32 NS
CL11
D3 1.22 5.82 NS
D5 1.29 17.81
D7 1.44 8.68 <
D10 1.35 4.97 <
CL4
D3 1.45 1.62
D5 1.96 13.3
D7 3.61 9.28 <
D10 3.36 4.29
CL3
D3 1.06 7.17 <
D5 1.24 22.99
D7 2.15 9.13 <
D10 2.0 4.26 <
CL2
D3 1.33 3.71
D5 3.14 16.59
D7 3.14 6.39
D10 3.09 2.3
tatistical comparison could not be performed on day 5 in allogene
point. All other data points contained 2-3 animals per group. Nadio-labeled cDNA probes for CXCL10, CXCL9, CXCL11, and GAPD
28us untreated control mice; CXCL10 and CCL5, day
6, P  .05). CXCL10 protein expression was con-
iderably higher in these non-GVHD mice, with no
tatistically signiﬁcant difference from animals in
lative conditioning. As described in the Methods section, BALB/c
w or allogeneic bone marrow plus allogeneic spleen cells (GVHD).
d to northern blot analysis. Blots were hybridized as described with
ng Myeloablative Conditioning
Mean Fold Increase in Expression
P-valueB6¡B6 BALB/c¡BALB/c
0.75 0.05 NS
0.58 0.19 NS
0.88 0.93 NS
0.48 0.92 NS
2.11 1 NS
1.11 0.52 NS
0.94 1.7 NS (0.06)
0.47 1.4 NS
1.77 1.23 <0.05
1.29 0.62 NS
1.3 2.41 <0.05
0.5 1.52
2.29 2.71 NS
1.08 0.44 NS
0.97 3.17 <0.01
0.36 1.89 NS (0.07)
1.52 2.21 NS
1.15 0.53 NS
0.78 1.3 NS
0.65 1.19 NS
ients because only one BALB/c¡B6 recipient was analyzed at this
signiﬁcant; ND, not determined.yeloab
marro
ubjectefollowi
-value
0.01
ND
0.01
(0.07)
(0.07)
ND
0.01
0.01
NS
ND
0.01
NS
0.01
ND
0.01
0.01
NS
ND
NS
NS
ic recipH. Three animals per group were studied at each time point.
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Chemokine Expression and GVHD
Bhich GVHD was induced (Figure 4B). However,
VHD induction led to further increases in levels of
ther chemokine proteins in the colon. On day 6
fter BMT there was a statistically signiﬁcant increase
n CCL2, CCL3, and CCL5 protein levels in animals
ith GVHD compared with syngeneic controls. Fur-
her, CCL2, CCL3, CCL5, and CXCL10 increased
igniﬁcantly (P  .05) from day 3 to day 6 after
MT in animals with GVHD. These results under-
core the notion that the GVH allogeneic response
igure 4. Systemic and local chemokine protein levels in respons
econstituted with syngeneic or allogeneic (BALB/c) BMCs. For in
ddition to BALB/c BMCs. Serum was collected on days 1, 3, a
ormal B6 sera. B, Protein was extracted from colon tissue as descri
hemokine expression was analyzed with the Luminex assay. Data f
ime point are depicted. Asterisks denote signiﬁcant differences (Preatly ampliﬁes chemokine upregulation after condi- t
B&MTioning and BMT systemically and locally in the
VHD target organs.
ffect of Conditioning Intensity and Strain on
hemokine Expression
To evaluate the effect of conditioning intensity on
hemokine expression in GVHD target organs, we
ompared tissue chemokine expression after nonmy-
loablative conditioning with that after lethal TBI.
cyclophosphamide-based nonmyeloablative condi-
nditioning and GVHR. A, B6 mice were lethally irradiated and
of GVHD, B6 animals received 1.5  107 BALB/c splenocytes in
after BMT. Dashed line indicates the chemokine levels detected in
the Methods section. Data from a single experiment are presented.
3 and  6 are shown. Means 	 SD of 2-5 animals per group per
. The experiment was performed twice with similar results.e to co
duction
nd 6
bed in
or dayioning regimen that permits mixed chimerism induc-
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6ion without GVHD was used [24,29] (see Methods).
ecause we have observed that BALB/c mice are more
usceptible than B6 recipients to the induction of
VHD by administration of DLI after mixed chimer-
sm was established with this regimen (M. Y. Mapara,
. Chakraverty, and M. Sykes, unpublished data), we
ypothesized that there might be strain differences in
hemokine upregulation in GVHD target tissues. We
herefore compared chemokine mRNA expression in
ALB/c and B6 mice at various times after nonmy-
loablative conditioning.
We examined expression of the chemokines
CL1, CCL5, CCL4, CCL3, CCL2, and CCL1 by
sing RNase protection assay analysis of epithelial
VHD target organs after nonmyeloablative condi-
ioning. Some of these chemokines were detectable
fter this conditioning but at signiﬁcantly lower levels
ompared to syngeneically reconstituted recipients of
yeloablative conditioning (data not shown). More-
ver, in contrast to myeloablative conditioning with
yngeneic BMT (Figure 3), expression of CXCR3-
inding chemokines in the large bowel was almost
ompletely undetectable after nonmyeloablative con-
itioning in the B6 and BALB/c strains (Figure 5).
herefore, our nonmyeloablative conditioning regi-
en using T-cell–depleting mAbs, cyclophosphamide
nd thymic irradiation leads to signiﬁcantly less che-
okine upregulation in GVHD target tissues com-
ared with lethal TBI.
No statistical difference was detected between the
wo recipient strains in chemokine expression in skin,
igure 5. Messenger RNA expression of CXCR3 ligands in the
olon after nonmyeloablative conditioning. As described in the Meth-
ds section, BALB/c or B6 mice were conditioned using the CTX-
ased nonmyeloablative conditioning regimen. Animals were killed
n days 3, 5, 7, and 10. RNA was extracted and subjected to
orthern blot analysis. Blots were hybridized as described in Mate-
ials and Methods with cDNAs against CXCL10, CXCL9,
XCL11, and GAPDH. A positive control RNA sample and probe
ere used on each blot to ascertain successful hybridization. Three
nimals per group were studied at each time point. c
30iver, or small bowel (data not shown). However, differ-
nces in the expression of some chemokine mRNAs
ere detected in the colons of B6 and BALB/c hosts that
eceived nonmyeloablative conditioning. As shown in
igure 6, BALB/c mice had signiﬁcantly greater in-
reases in the expression of CCL2, CXCL1, CCL3,
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*
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DAY 3 DAY 5
DAY 7 DAY 34
Fold increase in expression
igure 6. Strain dependence of chemokine mRNA expression after
onmyeloablative CTX-based conditioning. Chemokine mRNA
xpression was analyzed in the colon by RNase protection assay.
xpression intensity for each band was normalized within each
ample to the housekeeping gene (L32) and is presented relative to
xpression in normal mice. Means 	 SD of 2-3 animals per group
er time point are depicted. Asterisks denote signiﬁcant differences
P .05) between CTX-conditioned B6 and BALB/c animals at the
ndicated time points.
igure 7. Role of CXCR3 expression by donor cells in GVHD
nduction. BALB/c mice received 8-Gy TBI and were reconstituted
ith BMCs and splenocytes from WT (n 
 18) or CXCR3/ (n 

0) B6 mice. Recipients of CXCR3/ splenocytes showed signiﬁ-
antly accelerated early mortality at day 15 (P .05, Fisher exact test).
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Chemokine Expression and GVHD
BCL4, CCL11, CCL5, and XCL1 on day5 compared
ith B6 mice (P  .05). In addition, in contrast to B6
ice, CCL5 expression levels remained signiﬁcantly el-
vated until day34 in BALB/c but not in B6 mice. On
ay 34, B6 mice showed modestly but signiﬁcantly (com-
ared with BALB/c mice) higher levels of CCL11 and
CL3 mRNA. The greatest increase in expression over
aseline levels was attained in BALB/c mice for CCL2
mean relative expression, 8.07 	 .96) on day 5. Anal-
sis of other tissues (skin and liver) showed no signiﬁcant
pregulation of chemokine expression in response to
onmyeloablative conditioning (data not shown).
herefore, signiﬁcant strain differences were seen in the
pregulation of chemokines and its duration after non-
yeloablative conditioning.
nfluence of CXCR3 Expression by Donor T Cells
n the Development of GVHD
In view of the prominent expression of CXCR3
igands in the large bowel after myeloablative condi-
ioning, we hypothesized that these ligands may con-
ribute to the development of GVHD. We therefore
nduced GVHD in the B6¡BALB/c strain combina-
ion as described above and used CXCR3 gene-deﬁ-
ient (CXCR3 KO) mice as donors. Similarly treated
ecipients of syngeneic BM served as controls and
howed 100% survival. Surprisingly, we saw no sig-
iﬁcant difference in clinical GVHD scores or gut
njury in recipients of wild-type (WT) compared with
XCR3 KO B6 splenocytes (data not shown). Simi-
arly, there was no signiﬁcant difference in overall
urvival between groups. However, a trend toward
ccelerated early mortality was seen in animals that
eceived CXCR3 KO splenocytes (Figure 7), which
pproached statistical signiﬁcance (median survival
ime (MST) 26 versus 21 days for WT versus CXCR3
O donors, P 
 .06). Landmark analysis of survival
n day15 showed statistically signiﬁcantly increased
urvival (Fisher exact test, P  .05) in recipients of
T compared with CXCR3 KO splenocytes. The
xperiment was performed twice with similar results,
nd pooled data from both experiments are presented.
plenocytes of WT and KO mice did not differ in
-cell number or subset composition.
ISCUSSION
GVHD is a multistep inﬂammatory process that
omprises complex pathophysiologic events that are
riggered by allogeneic activation of donor T cells by
ost hematopoietically derived antigen-presenting
ells [6]. However, administration of nontolerant do-
or T cells after fully MHC-mismatched BMT does
ot lead to GVHD if their administration is delayed to
time point when conditioning-induced inﬂammationn the host environment has presumably disappeared i
B&MT7]. These DLIs can mediate powerful GVL effects
5]. In the clinical context, such pure LGVHRs have
hus far been difﬁcult to achieve reliably, possibly
ecause the proinﬂammatory milieu induced by con-
itioning is propagated by ongoing clinical or subclin-
cal GVH reactions or infections. Development of
VHD is a frequent and sometimes devastating com-
lication after DLI [30].
Understanding the mechanisms underlying the in-
ltration of donor lymphocytes into the epithelial
VHD target tissues might permit the development
f strategies for retaining donor T cells within the lym-
hohematopoietic system and thus prevent GVHD and
reserve GVL. We have currently addressed the hy-
othesis that tissue chemokine expression induced by
onditioning might promote initial T-cell inﬁltration
nd GVHD and that the level and pattern of chemo-
ine expression are dependent on the intensity and
ype of conditioning therapy. To our knowledge, this
s the ﬁrst study to address the effect of various con-
itioning therapies on the expression of chemokines in
VHD target organs.
Published data on the role of chemokines in
VHD are somewhat conﬂicting. Although CCL3
xpression in the lungs coincides with donor T-cell
nﬁltration [21,31], T cells from CCL3-deﬁcient mice
nduced an accelerated inﬂammatory pneumonitis
yndrome in a fully MHC-mismatched allogeneic
MT model [21,31]. Other studies have indicated that
onor T-cell–derived CCL3 is required for the re-
ruitment of donor CD8 T cells into the liver, lungs,
nd spleen [32], and T cells from CCL3 gene-deﬁ-
ient mice are impaired in their ability to induce
VHD [33] in class I but not in class II mismatched
MT, without minor histocompatibility differences.
n a parent to ﬁlial generation (P¡F1) model not
nvolving conditioning treatment, antibody blocking
f CCR5, the receptor for CCL3, signiﬁcantly de-
reased liver inﬁltration associated with GVHD [34].
Our investigation of chemokine expression in the
pithelial GVHD target organs demonstrated signiﬁ-
ant upregulation of chemokine gene expression in
yngeneic and allogeneic BMT recipients. Although
here was only a very subtle and transient increase of
CL2 in the liver after syngeneic BMT, we observed
signiﬁcant and sustained upregulation of various
hemokines (eg, CCL5, CCL3/4, and CXCL1) after
llogeneic BMT. Conditioning followed by syngeneic
MT led to marked, but short-lived, increases in che-
okine expression in the colon, particularly of the
igands of the CXCR3 receptor. CXCL10 has been
hown to be involved in murine colitis [35], thus
nderscoring the relevance of Th1 cells in this disease
nd paralleling our previous ﬁndings concerning the
elevance of Th1 cells in gut GVHD [22]. Thus, in
ccordance with our initial hypothesis that condition-
ng-induced tissue chemokine upregulation might be
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6n important factor in recruiting T cells into epithelial
VHD target tissues, moderate and short-lived up-
egulation of chemokines within those tissues was seen
fter lethal TBI in recipients of syngeneic inocula.
owever, after induction of GVHD, stronger and
ore sustained upregulation of chemokine expression
as observed in GVHD target tissues and, in the case
f the colon, was apparent before inﬁltration of the
arget tissues with donor T cells became evident. This
bservation suggests that the initial systemic alloge-
eic activation associated with GVHD propagates and
mpliﬁes an inﬂammatory milieu created initially by
onditioning alone, culminating in tissue inﬁltration.
owever, histology might not be sensitive enough to
etect minimal inﬁltration with donor T cells and we
annot rule out the possibility that chemokine expres-
ion at this early stage after BMT is due to T-cell
nﬁltration below the detection limit of standard his-
ology. As demonstrated by Beilhack et al [36], hom-
ng of donor T cells to secondary lymphoid organs is
n early event that occurs before tissue inﬁltration and
ay contribute to the chemokine expression observed
ocally in the gut and other GVHD target organs.
In contrast to myeloablative conditioning and syn-
eneic BMT, nonmyeloablative conditioning did not
pregulate expression of the CXCR3 ligand family in
he gut. However, low-level upregulation of other
hemokines was seen in the colon in response to
onmyeloablative conditioning. Thus, a decrease in
onditioning intensity correlates with a decreased in-
ammatory response in this GVHD target organ. Our
esults complement those of Wysocki et al [37] who
howed in unirradiated P¡F1 recipients that chemo-
ine expression is delayed for approximately 1 week
ompared with that in conditioned recipients, suggest-
ng that conditioning promotes early chemokine ex-
ression and GVHD, but that a GVH allogeneic
esponse alone can induce delayed chemokine expres-
ion in GVHD target organs. Our observation of an
arly increase in colon chemokine mRNA and protein
xpression in conditioned mice that received only syn-
eneic marrow, but not in the serum of the same
nimals, supports our interpretation that local, rather
han systemic, chemokine production induced by con-
itioning plays a role in promoting initial T-cell mi-
ration into GVHD target tissues. Marked strain dif-
erences in chemokine expression in the colon were
bserved after nonmyeloablative conditioning. In the
bsence of a GVHR, BALB/c mice had signiﬁcantly
ncreased chemokine levels in the colon compared
ith B6 mice on day 5 after conditioning. Although
ost chemokine mRNA expression levels returned to
aseline, BALB/c mice displayed increased CCL5 ex-
ression that was signiﬁcantly prolonged compared
ith that in B6 mice and remained high even by day
4. These observations are of interest because the
ALB/c mice that were used as recipients of alloge-
32eic BMT after this conditioning regimen showed
ncreased susceptibility to GVHD after DLI on day 35
ompared with B6 recipients (M. Y. Mapara, R.
hakraverty, and M. Sykes, unpublished data). How-
ver, there was no difference between B6 and BALB/c
ice in chemokine expression in the liver and skin.
CXCL10 and other members of this family have
een implicated in different immune reactions, in-
luding allograft rejection, airway hyperresponsive-
ess, and experimental allergic encephalomyelitis
16,17,20,38]. Our results clearly demonstrate that
XCR3 ligands are induced after conditioning and
yngeneic BMT but appear to be much more promi-
ent after allogeneic BMT, especially in the gut.
owever, to our surprise, CXCR3/ and WT donor
plenocytes induced similar GVHD, suggesting that
his pathway is not essential for GVHD of the intes-
ines or other organs.
Recently, Duffner et al [39] demonstrated that
XCR3 ligands are involved in the development of
VHD in a minor antigen-mismatched allogeneic
MT model, with no effect in a major mismatched strain
ombination. These investigators observed increased
umbers of interferon -expressing T cells in the spleens
f recipients of CXCR3 KO splenocytes. In our MHC-
ismatched GVHD model, we observed a trend toward
ccelerated mortality in recipients of CXCR3/ com-
ared with WT splenocytes. Thus far, we have been
nable to identify a pathobiologic cause for this acceler-
ted mortality. However, we speculate that, in keeping
ith the results of Duffner et al [39], increased cytokine-
roducing T-cell accumulation in the lymphoid tissues
f recipients of CXCR3/ T cells might lead to early,
ytokine-induced mortality. Alternatively, the increased
ortality observed in recipients of CXCR3/ spleno-
ytes might be attributable to a deﬁciency of CXCR3-
xpressing regulatory T-cell recruitment to the site of
nﬂammation.
Inﬂammatory chemokines and their receptors are
ighly redundant, so that inhibition of 1 particular
hemokine family might not be sufﬁcient to block
issue inﬁltration in the highly proinﬂammatory mi-
ieu that promotes GVHD. More global strategies to
ffect lymphocyte trafﬁcking might be more effective
han interfering with selected chemokines. One such
pproach uses FTY-720, a sphingosine-1-phosphate ag-
nist, which can prevent the development of GVHD in
haplotype-mismatched setting, presumably by trapping
ymphocytes within the lymphohematopoietic system
25]. Other approaches could target multiple chemo-
ines by taking advantage of silent decoy [40] or recom-
inant viral decoy receptors that could act as scavengers
or inﬂammatory chemokines [41]. Further, chemo-
ines could be targeted by small molecules that inter-
ere with the signaling events that occur downstream
f G-protein–coupled receptors.In conclusion, our results demonstrate that che-
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Chemokine Expression and GVHD
Bokine expression in GVHD target organs after con-
itioning is inﬂuenced by the time since conditioning,
onditioning intensity, and recipient strain. Although
xpression of CXCL10 and its family members is
arkedly upregulated after allogeneic BMT, espe-
ially in the gut, GVHD and tissue injury can occur in
he absence of CXCR3 expression on donor T cells in
ully MHC-mismatched BMT.
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